Leonard Zemel
Endocrinology, Diabetes & Metabolism · Denver, CONPI 1447256045
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2021 at $7,528 and has fallen 98.8% since, to $91 in 2025.
Across 562 payments — averaging $32.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Sanofi-aventis U.S. LLC$4K
- Tandem Diabetes Care, Inc.$2K
- Mannkind Corporation$1K
- AstraZeneca$1K
- Mylan Specialty L.p.$1K
- plus $5K from 33 others
Across 1,874 payments — averaging $378.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$409K
- AbbVie$171K
- Gilead$44K
- AstraZeneca$42K
- Boehringer Ingelheim$35K
- Boehringer Ingelheim Pharma GmbH & Co.kg$5K
- plus $3K from 1 others
What the payments were for
- Consulting fees$3,52819%
- Speaking & faculty fees$3,92021%
- Food & beverage$11,00960%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 143 | $4,192 |
| Sanofi-aventis U.S. LLC | 35 | $3,948 |
| Tandem Diabetes Care, Inc. | 6 | $1,700 |
| Mannkind Corporation | 79 | $1,454 |
| AstraZeneca(2 entities) | 59 | $1,391 |
| Mylan Specialty L.p. | 1 | $1,038 |
| Lilly USA, LLC | 35 | $612 |
| Abbott | 12 | $468 |
| Amgen(2 entities) | 16 | $412 |
| Antares Pharma, Inc. | 23 | $368 |
| Amarin Pharma, Inc. | 14 | $326 |
| AbbVie | 11 | $290 |
| Amneal Pharmaceuticals LLC | 20 | $280 |
| Boehringer Ingelheim | 16 | $272 |
| IBSA Pharma Inc. | 12 | $227 |
| Merck | 15 | $226 |
| Medtronic(2 entities) | 7 | $146 |
| Dexcom, Inc. | 7 | $128 |
| Valeritas, Inc. | 7 | $125 |
| Lifescan, Inc. | 6 | $118 |
| Insulet Corporation | 6 | $100 |
| Ultragenyx Pharmaceutical Inc. | 5 | $94 |
| Bayer | 4 | $75 |
| Johnson & Johnson | 3 | $73 |
| Corcept Therapeutics | 4 | $64 |
| Senseonics, Incorporated | 2 | $49 |
| Recordati_rare_diseases_inc. | 1 | $41 |
| Zealand Pharma US, Inc. | 1 | $35 |
| Clarus Therapeutics Inc. | 2 | $33 |
| Acella Pharmaceuticals, LLC | 1 | $31 |
| Radius Health, Inc. | 1 | $26 |
| Gilead | 1 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| BD | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$2,161
- t-slim insulin pump$1,250
- t:slim X2 insulin pump$450
- FARXIGA$252
- AFREZZA$249
- TZIELD$140
- Vascepa$136
- FREESTYLE LIBRE 3$130
- Wegovy$125
- Saxenda$122
- EVENITY$122
- Synthroid$108
- DIABETES - DISEASE$104
How this compares
$18,501 in reported general payments places this provider in the 80th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $28,832 |
| Metformin Hcl | 20 | $337 |
| Levothyroxine Sodium | 38 | $304 |
| Atorvastatin Calcium | 22 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $4,192 | $28,83214 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $280 | $30438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Denver
- Daniel BessesenDenver$34K
- Michael LoughnerDenver$32K
- Alex GoldsmithDenver$12K
- Daniel CitronDenver$8K
- Sarah BullDenver$4K
- Leslie GamacheDenver$4K
- Claudia PanzerDenver$3K
- Sheila MaierDenver$2K
- Karin HickeyDenver$2K
- Gregory LundDenver$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.